A Randomized, Double-blind, Placebo-Controlled, Ascending Multiple-Dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of VIA-3196 in Healthy Subjects.
Phase of Trial: Phase I
Latest Information Update: 01 Oct 2013
At a glance
- Drugs MGL-3196 (Primary)
- Indications Dyslipidaemias; Hypercholesterolaemia
- Focus Adverse reactions
- 16 Apr 2013 Results discussed in a First Times Disclosures session at National Meeting of the American Chemical Society.
- 29 Nov 2012 Status changed from recruiting to completed.
- 07 Nov 2012 Results presented at the 85th Annual Scientific Sessions of the American Heart Association.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History